TrialInternational journal of clinical pharmacy2024

A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS).

David Young et al.PubMed ↗Publisher ↗

No numbers read from the abstract.